Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial.

MLA

Perrone, Francesco, et al. “Adjuvant Zoledronic Acid and Letrozole plus Ovarian Function Suppression in Premenopausal Breast Cancer: HOBOE Phase 3 Randomised Trial.” European Journal of Cancer (Oxford, England : 1990), vol. 118, Sept. 2019, pp. 178–86. EBSCOhost, https://doi.org/10.1016/j.ejca.2019.05.004.

APA

Perrone, F., De Laurentiis, M., De Placido, S., Orditura, M., Cinieri, S., Riccardi, F., Ribecco, A. S., Putzu, C., Del Mastro, L., Rossi, E., Tinessa, V., Mosconi, A. M., Nuzzo, F., Di Rella, F., Gravina, A., Iodice, G., Landi, G., Pacilio, C., Forestieri, V., … Gallo, C. (2019). Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial. European Journal of Cancer (Oxford, England : 1990), 118, 178–186. https://doi.org/10.1016/j.ejca.2019.05.004

Chicago

Perrone, Francesco, Michelino De Laurentiis, Sabino De Placido, Michele Orditura, Saverio Cinieri, Ferdinando Riccardi, Angela Stefania Ribecco, et al. 2019. “Adjuvant Zoledronic Acid and Letrozole plus Ovarian Function Suppression in Premenopausal Breast Cancer: HOBOE Phase 3 Randomised Trial.” European Journal of Cancer (Oxford, England : 1990) 118 (September): 178–86. doi:10.1016/j.ejca.2019.05.004.